

Dear

FREEDOM OF INFORMATION – MCL PRESCRIBING

I write in response to your request for information in relation to Mantle Cell Lymphoma (MCL) prescribing.

Question:

1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

Answer:

I am advised that this information is not held in a centrally extractable format. We would only be able to provide inpatient stays where a diagnosis of MCL is attached to that stay. This would not include any treatment done in an outpatient setting like radiotherapy.

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files **relating to patients** over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

Answer:

2a	BR (Bendamustine + rituximab)	≤5
2b	VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)	Nil
2c	R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)	7
2d	R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose	≤5

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

	Cytarabine)	
2e	CVP (cyclophosphamide, vincristine and prednisolone)	Nil
2f	Brukinsa (zanubrutinib)	≤5
2g	Imbruvica (ibrutinib)	≤5
2h	Velcade (bortezomib) + chemotherapy	Nil
2i	Tecartus (brexucabtegene autoleucl)	≤5
2j	R-BAC (rituximab, bendamustine and cytarabine)	≤5
2k	R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)	Nil
2l	Any other systemic anti-cancer therapy	17
2m	Wait and watch (monitoring only, no active treatment)	N>A

Question:

3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: *For this question, please only count patients that have received the below treatments for the first time.*

Answer:

3a	BR (Bendamustine + rituximab)	≤5
3b	VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)	Nil
3c	R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)	≤5
3d	R-maxi-CHOP or Nordic Protocol (<i>R-CHOP alternated with Rituximab+ High-dose Cytarabine</i>)	≤5
3e	CVP (cyclophosphamide, vincristine and prednisolone)	Nil
3f	Brukinsa (zanubrutinib)	≤5
3g	Imbruvica (ibrutinib)	≤5
3h	Velcade (bortezomib) + chemotherapy	Nil
3i	Tecartus (CAR-T)	≤5
3j	R-BAC (rituximab, bendamustine and cytarabine)	≤5
3k	R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)	Nil
3l	Any other systemic anti-cancer therapy	9
3m	Wait and watch (monitoring only, no active treatment)	N-A

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.



Answer:

Currently NHS Lothian are not participating in any trials for the treatment of mantle cell lymphoma (MCL).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive